New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease. [electronic resource]
Producer: 20110719Description: 443-58 p. digitalISSN:- 1558-1497
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine -- adverse effects
- Analysis of Variance
- Animals
- Antibodies -- pharmacology
- Antiparkinson Agents -- pharmacology
- Apomorphine -- pharmacology
- Chemokine CX3CL1 -- adverse effects
- DNA Nucleotidylexotransferase -- pharmacology
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Drug Interactions
- Gene Expression Regulation -- drug effects
- Levodopa -- pharmacology
- Male
- Mental Disorders -- etiology
- Nerve Tissue Proteins -- metabolism
- Parkinson Disease -- complications
- Rats
- Rats, Sprague-Dawley
- Reaction Time -- drug effects
- Stereotyped Behavior -- drug effects
- Substantia Nigra -- metabolism
- Tyrosine 3-Monooxygenase -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.